Annexon Given Overweight Rating at Cantor Fitzgerald
| ANNX Stock | USD 4.85 0.02 0.41% |
Slightly above 64% of Annexon's investor base is looking to short. The analysis of the overall investor sentiment regarding Annexon suggests that many traders are alarmed. Annexon's investing sentiment can be driven by a variety of factors including economic data, Annexon's earnings reports, geopolitical events, and overall market trends.
Annexon |
Cantor Fitzgerald reiterated their overweight rating on shares of Annexon in a research report report published on Monday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Annexons FY2023 earnings at EPS. A number of other equities research analysts have also recently issued reports on ANNX. HC Wainwright reissued a buy
Read at thelincolnianonline.com
 |
Annexon Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Annexon can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Annexon Fundamental Analysis
We analyze Annexon's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annexon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annexon based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Annexon is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Annexon Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Annexon stock to make a market-neutral strategy. Peer analysis of Annexon could also be used in its relative valuation, which is a method of valuing Annexon by comparing valuation metrics with similar companies.
Peers
Annexon Related Equities
| INZY | Inozyme Pharma | 9.56 | ||||
| HEPA | Hepion Pharmaceuticals | 3.28 | ||||
| BPMC | Blueprint Medicines | 0.87 | ||||
| ZURA | Zura Bio | 0.72 | ||||
| XFOR | X4 Pharmaceuticals | 0.45 | ||||
| WVE | Wave Life | 0.40 | ||||
| GPCR | Structure Therapeutics | 0.06 | ||||
| RCUS | Arcus Biosciences | 0.11 | ||||
| CNSP | Cns Pharmaceuticals | 0.91 | ||||
| CGEM | Cullinan Oncology | 1.18 | ||||
| INAB | In8bio | 1.61 | ||||
| DAWN | Day One | 1.86 | ||||
| ABOS | Acumen Pharmaceuticals | 3.56 | ||||
| RLAY | Relay Therapeutics | 5.74 | ||||
| AMLX | Amylyx Pharmaceuticals | 7.58 | ||||
| IMMX | Immix Biopharma | 13.78 |
Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.